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Abstract
Background: Due to the detrimental effect of blood contamination on the physico-chemical properties of mineral
trioxide aggregate (MTA), obtaining an effective hemostasis in the surgical crypt during apical surgery is of
paramount importance. The purpose of this in vivo study was to analyze the effect of Ankaferd Blood Stopper® (ABS)
contamination on the biocompatibility of MTA.
Methods: Forty of 56 Wistar–Albino rats were divided randomly and equally into two groups (MTA and MTA-ABS)
according to whether or not a hemostatic agent was used. The remaining 16 rats were designated as the control
group. Rats in the experimental groups received freshly mixed MTA-Angelus in polyethylene tubes, which were inserted
into monocortical bore holes created in their tibias. In the MTA-ABS group only, 0.5 mL of ABS solution was
administered topically on the defect sites followed by implantation of MTA tubes. Inflammation, foreign-body reaction
(FBR), necrosis, fibrosis, and new bone formation (NBF) were studied 7, 30, 60, and 90 days after implantation.
Results: On day7, statistically significant differences were found in tissue reactions with regard to NBF and necrosis
(p = 0.044 and p = 0.024, respectively), the latter being observed in 40 % of the samples only in the MTA-ABS group.
Slight inflammation in all groups was confined to day-7 only. Mild necrosis was present in the MTA-ABS group only
on day-7. Severity of the foreign body reaction and fibrosis was limited. New bone formation increased gradually
over time in all groups, reaching a maximum on day-90.
Conclusions: MTA and ABS-contaminated MTA are equally biocompatible. ABS does not impair the properties of
MTA.
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Background
Periapical surgery is commonly comprised of root-end re-
section, apical cavitation, and root-end filling to seal the
communication between the periapical tissues and the
root canal system [1]. An “ideal” root-end filling material
should have properties like; easy handling, good biocom-
patibility and apical sealability at the root apex to prevent
the egress of bacteria, and bacterial byproducts [2, 3]. It
should also be insoluble in body fluids such as blood,
saliva, and tissue fluid [4, 5]. Unfortunately, there is no
ideal material that fulfills all of these requirements.
Various root-end filling materials have been suggested
[6]. The calcium silicate-based compound mineral trioxide
aggregate (MTA) has been compared with other root-end
filling materials and hypothesized to be a “near-to-ideal
substance” [7]. MTA is used widely in root-end filling,
pulp capping, perforation repair, and in the treatment of
immature apices. MTA is employed in these conditions
because of its biocompatibility, antibacterial nature, ability
to set in moist environments, and because it acts as a po-
tential seal against bacterial penetration [8].
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In endodontic surgery, blood comes into contact with
(and often becomes incorporated into) MTA during or
after its placement. This contamination has detrimental
effects on its surface microhardness, compressive
strength, bond strength and marginal adaptation [9].
Blood contamination of unset MTA adversely affects the
setting reaction and mechanical strength of the material
[10]. When considering the clinical uses of MTA, its
physical properties are important factors in achieving a
good seal between the root canal and the external sur-
face of the root [9]. Therefore, in using MTA, attempts
should be made to control bleeding [9, 10].
Various local hemostatic agents have been used in oral
and maxillofacial surgery [11]. Ankaferd Blood Stopper®
(ABS) (Ankaferd Sağlık ürünleri A.Ş., Istanbul, Turkey)
is an extract from medicinal plants that have been used
for centuries in Turkish traditional medicine as a
hemostatic agent. ABS consists of a standardized mix-
ture of several plants: Urtica dioica (6.0 g/100 ml), Vitis
vinifera (8.0 mg/100 ml), Alpinia officinarum (7.0 mg/
100 ml), Thymus vulgaris (5.0 mg/100 ml) and Glycyr-
rhiza glabra (7.0 mg/100 ml) [12]. Each of these plants
has an impact on cellular proliferation, vascular dynam-
ics, angiogenesis, blood cells, cell mediators and endo-
thelia [13]. Each constituent, if used separately, has
interesting biologic effects. U.diocia can elicit vasorelax-
ation (mediated by the release of endothelial nitric oxide
and the opening of potassium channels) as well as a
negative inotropic action. Vitis vinifera exerts anticarci-
nogenic and antiatherosclerotic effects. Alpina offici-
narum inhibits nitric oxide production in macrophages.
Thymus vulgaris has antioxidative actions such as pre-
vention of peroxidation. Glycyrrhiza glabra has anti-
inflammatory, antithrombin, antiplatelet, antioxidant,
antiatherosclerotic, and anticarcinogenic effects [13, 14].
In addition, ABS has been found to be as effective as
Surgicel® for achieving hemostasis in animal models [15,
16]. Moreover, ABS can be used to create a blood-free
tooth surface during application of brackets on surgically
exposed impacted teeth [13, 14]. ABS has also been used
successfully for: dental extractions in patients undergoing
antithrombotic treatment with acetylsalicylic acid and war-
farin sodium without interrupting and/or altering the anti-
coagulant regimens [17]; in patients with hemorragic
diathesis [18]; and in the treatment of acute and profuse
bleeding of the gastrointestinal tract [19].
Reactions in tissues caused by hemostatic agents
are important for the reliability of the materials used
[20, 21]. Although ABS is widely used in endodontic
surgery as a hemostatic agent [13], data regarding to
its effects on root-end filling materials in animal ex-
periments (devised for the investigation of their bio-
compatibility) are lacking. Thus, the aim of the
present in vivo study was to evaluate and compare
the effect of ABS on the early and long-term tissue
reactions of MTA in a wound healing model at rat
tibias. This is the first histopathologic study to ascer-
tain whether ABS, when used as an hemostatic agent,
affects the biocompatibility of MTA.
Methods
Animal care and sample grouping
The study was carried out in various departments within
Istanbul University (Istanbul, Turkey). Care and use of
laboratory animals was according to the criteria set by
the Committee on Animal Research within Istanbul Uni-
versity (protocol number: 43/09). Rats were obtained
from the Center of Experimental Medical Research of
Istanbul University.
Fifty-six Wistar–Albino male rats (4–6 months,
250–300 g) were housed in groups of four per cage,
fed standard pellets and water in a temperature-
regulated room (22 °C, 55 % humidity, 12-h light–
dark cycle), and allowed to mobilize freely. Forty rats
were divided randomly and equally into two experi-
mental groups according to whether or not a
hemostatic agent was used. The remaining 16 rats
were designated as the control group.
Intraosseous surgical procedure
Each animal underwent a general anesthetic procedure by
the injection of ketamine hydrochloride (10 %; Alfamine®;
15 mg/kg body weight, i.m.) and xylazine hydrochloride
(2 %; Alfazyne®; 60 mg/kg, i.m.). After shaving the left and
right hind limbs, rats were positioned in the ventral decubi-
tus position. Antisepsis (10 % povidone-iodine solution
(Isosol®, Central Laboratory, Istanbul)) was carried out over
shaved areas. An incision (≈15 mm) was made at the lateral
aspect of the anterior border of the tibia until the tibia was
reached. After reflection of the periosteum, a monocortical
circular defect (diameter, 1.5 mm) was created at the anter-
ior portion of the diaphysis of both tibias until the bone
marrow was reached. These defects were drilled using a
round carbide burr in a low-speed handpiece under con-
stant irrigation with physiologic (0.9 %) sterile saline solu-
tion to prevent overheating and necrosis of bone tissue.
MTA-Angelus (Angelus Indústria de Produtos
Odontológicos, Londrina, Brazil) was mixed according
to the manufacturer’s instructions. Then, the freshly
mixed cement was introduced into sterile polyethyl-
ene (non-toxic, intravenous catheter, 18 G) tubes (ex-
ternal diameter, 1.2 mm; length, 10 mm; sealed at
one end) with the aid of a syringe having a needle
compatible with the inner diameter of the tubes.
Empty tubes were used for rats in the control group.
Tubes were introduced so that they projected into the
bone-marrow compartment and their lateral walls
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were parallel to the long axis of the tibia with the
closed ends pointing towards the knee joint [22].
In the MTA-ABS group, 0.5 mL of ABS solution
was administered topically on the defect sites using
an insulin syringe, after which the tubes containing
MTA-Angelus were implanted into the right tibias. In
the MTA group, local hemostasis was achieved with
direct packing with gauze on the defect sites, and
then the tubes containing MTA-Angelus were im-
planted into the left tibias. In the control group, local
hemostasis was maintained in the same manner as
that in the MTA group, and then empty tubes were
inserted into both tibias. The muscle layer was su-
tured with absorbable 4/0 gut sutures, and the skin
closed with 3/0 silk thread (M.E.D). No antibiotic was
given and the rats were observed postoperatively. All
animals survived the indicated time periods without
complications.
Histological procedures
After each time period (7, 30, 60, and 90 days), 14 rats were
sacrified with an overdose of ketamine hydrochloride
(50 mg/kg). Entire tibias were isolated by gross dissection,
fixed in 10 % formalin for 24 h, decalcified in 20 % formic
acid, and processed for embedding in paraffin. Sections
were cut parallel to the long axis of the tubes at 7 μm,
mounted on slides, and stained with hematoxylin and eosin
(H&E). Slides were analyzed and photographed at different
magnifications in five areas with a light microscope (Eclipse
E600; Nikon, Tokyo, Japan) coupled with a digital camera,
by an oral pathologist (V.O) blinded to the study protocol.
Morphometric analysis
To estimate the level of inflammation and recovery in
bone-marrow tissue adjacent to the open end of each
tube, all sections were analyzed to evaluate inflamma-
tion, FBR, fibrosis, NBF, and necrosis. When evaluating





Inflammatory response (Mean ± SD) 7 days 1 ± 0 1 ± 0 0,75 ± 0,46 0,075
30 days 0 ± 0 0 ± 0 0 ± 0 1,000
60 days 0 ± 0 0 ± 0 0 ± 0 1,000
90 days 0 ± 0 0 ± 0 0 ± 0 1,000
p 0,001* 0,001* 0,001*
Foreign body reaction (Mean ± SD) 7 days 0,2 ± 0,42 0,3 ± 0,48 0 ± 0 0,262
30 days 0,1 ± 0,32 0,2 ± 0,42 0 ± 0 0,407
60 days 0 ± 0 0,1 ± 0,32 0 ± 0 0,407
90 days 0 ± 0 0 ± 0 0 ± 0 1,000
p 0,276 0,281 1,000
Fibrosis (Mean ± SD) 7 days 1 ± 0 1,4 ± 0,52 1,25 ± 0,46 0,097
30 days 0,7 ± 0,48 0,4 ± 0,52 0,38 ± 0,52 0,300
60 days 0,1 ± 0,32 0,1 ± 0,32 0,25 ± 0,46 0,603
90 days 0,2 ± 0,42 0,5 ± 0,53 0,75 ± 0,46 0,071
p 0,001* 0,001* 0,004*
New bone formation (Mean ± SD) 7 days 1,7 ± 0,48 1,6 ± 0,52 1,13 ± 0,35 0,044***
30 days 2,3 ± 0,48 2,2 ± 0,42 2,38 ± 0,74 0,681
60 days 2,7 ± 0,48 2,6 ± 0,52 2,25 ± 0,46 0,154
90 days 3 ± 0 3 ± 0 3 ± 0 1,000
p 0,001* 0,001* 0,001*
Necrosis [n(%)] 7 days 0(%0) 4(%40) 0(%0) 0,024***
30 days 0(%0) 0(%0) 0(%0) -
60 days 0(%0) 0(%0) 0(%0) -
90 days 0(%0) 0(%0) 0(%0) -
p - 0,009** -
MTA Mineral trioxide aggregate, ABS Ankaferd blood stopper, SD Standart deviation; *Significant difference within the groups at p < 0.05; **Significant difference
within the groups at p < 0.01; ***Significant difference among the groups at p < 0.05; Bold data confines only to p values both within or among the groups
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FBR, the presence of foreign body giant cells and when
evaluating inflammation, that of lymphocytes and plas-
mocytes were considered as basis. In the NBF, the tra-
becular, web-like woven bone or the thin lamellar bone
tissue which tends to cover the area adjacent to the open
end of the tube were considered as essentials. The bone
trabecules without osteoblasts around, were considered
as structures belonging to pristine bone and were
neglected. While evaluating necrosis, at the open end of
the tubes, the loss of the characteristic staining capabil-
ity of cellular nuclei and disappearance of the details of
cellular morphology, forming the classical appearance of
cell death was considered as necrosis. Scores for these
reactions (except for necrosis) were estimated by meas-
uring the magnitude of the areas occupied by the tissue
reactions in a standardized microscopic field at x40
magnification at the open end of the tubes by using an
image analysis software (Olympus analySİS FIVE, Tokyo,
Japan). A cell percentage of 0–25 % was scored semiquan-
titatively as “none” (0), 25–50 % as “mild” (1), 50–75 % as
“moderate” (2), and 75–100 % as “severe” (3), [6, 13].
Scores for necrosis were determined according to its pres-
ence (1) or absence (0), [6].
Statistical analysis
Values for the severity of inflammation, FBR, fibrosis as
well as the level of NBF were compared using the Krus-
kal–Wallis and the Mann–Whitney U non-parametric
tests. Values for the presence or absence of necrosis
were compared with the Fisher–Freeman–Halton test.
Analyses were done using SPSS v22.0 (IBM, Armonk,
NY, USA) with (p < 0.05) being considered significant.
Results
At the end of all time periods, wound healing was satis-
factory for all rats and all implanted biomaterials
remained in situ. Scores and percentages for inflamma-
tion, FBR, necrosis, fibrosis, and NBF in all groups are
shown in Tables 1–2 and illustrated in Fig. 1 (see Add-
itional file 1, for a detailed version of scores as raw data).
Representative histologic images of specimens in all study
groups at all times are illustrated in Figs. 2, 3 and 4.






7 days 30 days 60 days 90 days
New Bone Formation MTA (%) Severe 0 30 70 100
Moderate 70 70 30 0
Mild 30 0 0 0
None 0 0 0 0
MTA-ABS (%) Severe 0 20 60 100
Moderate 60 80 40 0
Mild 40 0 0 0
None 0 0 0 0
Control (%) Severe 0 50 25 100
Moderate 12.5 37.5 75 0
Mild 87.5 12.5 0 0
None 0 0 0 0
Fibrosis MTA (%) Severe 0 0 0 0
Moderate 0 0 0 0
Mild 100 70 10 20
None 0 0 0 0
MTA-ABS (%) Severe 0 0 0 0
Moderate 40 0 10 0
Mild 60 40 0 50
None 0 0 0 0
Control (%) Severe 0 0 0 0
Moderate 25 0 0 0
Mild 75 37.5 25 75
None 0 0 0 0
MTA Mineral trioxide aggregate, ABS Ankaferd blood stopper
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An inflammatory reaction was observed in the MTA,
MTA-ABS and the control groups only at the first study
interval on day 7, being absent in the remaining study
intervals. No such reaction was present in any of the
groups at 30, 60, or 90 days. There were no significant
differences (p > 0.05) among the study groups on day-7,
whereas significant differences (p < 0.05) were detected
when day-7 was compared with the inflammation at 30,
60, or 90 days.
At the open ends of the inserted tubes, macrophages
in the connective tissue were detected to phagocyte the
implanted biomaterial at the junctional area, where the
connective tissue came in touch with the biomaterial,
forming foreign body giant cells which induced a foreign
body reaction and which was observed in two samples
in the MTA group and in three samples in the MTA-
ABS group on day 7; in one sample in the MTA and in
two samples in the MTA-ABS groups on day 30; and
only in one sample in the MTA-ABS group on day 60.
Extent of FBRs among groups was not significant (p >
0.05) at 7, 30, 60, or 90 days. At these intervals, a FBR
was not present in the control group. There were no sig-
nificant differences (p > 0.05) among time periods in any
group.
There was no necrosis in the MTA group or the con-
trol group on day-7. Necrosis was present in the MTA-
ABS group only on day-7 and differences between this
group and the other two groups were significant (p <
0.05). A significant difference (p < 0.01) was present only
in the MTA-ABS group on day-7 among the time inter-
vals used.
With regard to the severity of fibrosis, no significant
differences (p > 0.05) were present among MTA, MTA-
ABS, and control groups at 7, 30, 60, or 90 days. How-
ever, significant differences (p < 0.05) were detected
among time periods in all groups. Distribution of per-
centages of fibrosis in each study group at time intervals
is shown in Table 2.
Intensity of NBF showed a significant difference (p <
0.05) among the study groups only on day-7. In the con-
trol group, the prevalence of NBF was significantly lower
than either of the MTA and the MTA-ABS groups, but
differences in NBF between these two groups were not
significant at 30, 60, or 90 days. Comparison of the preva-
lence of NBF among groups showed significant differences
(p < 0.05) during time periods, but the prevalence of NBF
of specimens in each group varied with time (Table 2).
Discussion
Intraosseous models provide an appropriate environ-
ment for in vivo testing of the biomaterials used in end-
odontic surgery. The biomaterials to be tested for
Fig. 1 The mean and standart deviation of reaction scores in all groups at time intervals. a Inflammation; b Foreign body reaction; c Fibrosis and
d New bone formation
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biocompatibility by intraosseous implantation are usually
placed into the tibias and femurs of small laboratory ani-
mals like rats and guinea-pigs [13, 18, 22–24]. When a
root end filling material is placed into the root end cav-
ity, it comes into contact with periradicular tissues.
Therefore, the reaction of bone to a biomaterial allows
one to evaluate its biocompatibility. Thus, we have pre-
ferred to test the osseous reaction to our materials using
the tibias of Wistar rats in a similar manner as reported
in the endodontic literature [3, 7, 13, 22, 23]. Also in
these studies, one can see that the study periods vary
from author to author and there are no standart time
points. If one desires immediate or early reactions, 7-
day, 15-day and 30-day intervals are chosen. For long
term reactions, the study intervals like 60 and 90-days
can be added. Olsen et al. [22] have selected 7-14-21-56-
100 days for time points.
A mild temporary inflammatory reaction was lim-
ited to 7 days in all groups. The inflammatory reac-
tion in the control group was attributed only to the
trauma produced during the tube placement [25].
However, in MTA and MTA-ABS groups, the high
pH (owing to the release of calcium hydroxide when
MTA was mixed with water), production of heat by an
exothermic reaction during the setting of MTA, release of
proinflammatory cytokines such as interleukin-1 and 6
during the process, and the aluminium content of the
MTA, had additive effects on the inflammation caused by
the surgical trauma [2, 3, 26].
Necrosis can be caused by almost any type of severe
injury. In this study, tissue necrosis was only found, on
day 7, in 4 samples of the MTA-ABS group where the
possible cause may be the irritating effect of the material
itself and the contamination with ABS. The disappear-
ance of necrosis on day 30 may be related to the elimin-
ation of the acute irritating potential of the implanted
material. Nevertheless, it has been shown that ABS is
not toxic or allergenic, but has antibacterial and anti-
inflammatory properties. ABS did not cause necrosis
in bone tissue or defect areas according to histology.
Moreover, ABS has been shown to reduce the preva-
lance of inflammation and necrosis in animal experi-
ments [13, 18, 27]. Thus, ABS may not have caused
this inflammation.
A FBR can occur if a foreign material is inserted into tis-
sues. Fibroblasts proliferate and surround the foreign body.
However, the latter is insoluble or indigestible by phago-
cytes, and is isolated by connective tissue [28]. FBRs were
documented in the MTA and the MTA-ABS groups. In
addition to all these, the FBR in the MTA-ABS group was
found to be higher than that of the MTA group, the
difference being statistically insignificant which may be
Fig. 2 Tissue reactions in the control group. 7 days: a Thin trabeculae of new bone (arrow) was observed at the open end of the tube (H&E,x400).
30 days: b New bone formation (arrows) adjacent to the tube end (H&E,x400). 60 days: c New bone became lamellar (arrow) at the open end of the
tube. Normocellular bone marrow (bold arrow) is seen under the bone (H&E,x200). 90 days: d Lamellar bone (arrows) surrounding fatty bone marrow
(bold arrow) getting into the tube (H&E,x40)
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attributed to the limited number of rats allowed due
to ethical considerations. In the control group, a FBR
was not detected at any time interval. In our opinion,
the FBR in these two groups was owing to modified
cells (epitheloid cells), remnants, constituents of min-
eral origin (waxy or oily remains), or complex poly-
saccharides and polymers [29].
Fundamentally, a connective-tissue reaction is a re-
sponse of tissues to injury, and the damage tends to
be repaired [29]. Severity of fibrosis among MTA,
MTA-ABS, and control groups was very mild and was
not significant at any time interval. Hence, the in-
flammation observed on day-7 was not persistent, and
subsided in a short time. A stepwise increase in NBF
was detected in all groups but a significant difference
was not observed at any interval. In the control
group, NBF increased but to a lesser extent. Distribu-
tion of NBF variations at time intervals is shown in
Table 2.
All materials evoked an inflammatory reaction on day-
7, this finding is in accordance with those of other stud-
ies [2, 3, 7]. Slight inflammation on day-7 and its
absence at 30 days suggest that MTA and ABS-
contaminated MTA had acceptable biocompatibility [8].
Absence of inflammation followed by NBF in surround-
ing areas owing to their osteoconductive properties,
seems to be the best proof of biocompatibility for MTA
and ABS-contaminated MTA [23].
An acceptable level of biocompatibility of a material
ranges between no inflammatory response upon im-
plantation, to an initial severe response that diminishes
over time [30]. A biocompatibility scale has been devised
by Moretton et al. [2] comprising of four levels, each as-
sociated with the severity of inflammation and its vari-
ation over time. This scale is used to assess the clinical
relevance of findings of implantation experiments in ani-
mals whereby the first three levels denote an acceptable
degree of biocompatibility. In the present study, the in-
flammatory response was mild and confined to the first
week. According to the biocompatibility scale, MTA and
ABS-contaminated MTA were biocompatible materials
with almost identical effects on neighboring tissues. This
mild response shows that both materials had better
biocompatibility than those reported by Moretton et al.
[2] and other scholars [3, 31–34]. The “gold standard” of
biocompatibility is bone formation [24]. The absence of
inflammation, together with a greater amount of hard-
tissue formation against MTA and ABS-contaminated
MTA, indicates their biocompatibility [8, 23].
MTA and ABS-contaminated MTA had similar effects
throughout this 90-day study. Accordingly, ABS neither
increased nor decreased the characteristic features of
Fig. 3 Tissue reactions in the MTA group. 7 days: a Fibrous connective tissue (bold arrow) and new bone trabeculae (arrows) were seen at the
open end of the tube (H&E,x200). 30 days: b Lamellar bone formation (arrow) and residual MTA (bold arrow) were observed (H&E,x100). 60 days: c
New bone formation (arrow) and normocellular bone marrow (bold arrow) were seen at the open end (H&E,x200). 90 days: d Mature lamellar
bone (arrow) and normocellular bone marrow (bold arrow) (H&E,x200)
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MTA but exerted a hemostatic effect. The “ideal”
hemostatic agent is one that is safe, sterile, easy to apply,
visible in the cavity, easy to remove, non-irritant, dis-
solves and degrades without interfering with periapical
healing, and is an integral part of current surgical proto-
cols [11, 17, 21].
Interestingly, ABS possesses features or functions not
dissimilar to those mentioned above. Emes and col-
leagues, using an in vitro cell-culture model of rat fibro-
blasts, [35] stated that ABS, fibrin glue, and tranexamic
acid may negatively affect tissue healing. However, other
scholars have stated that ABS increases NBF in the early
bone-healing period [13, 18]. Our findings show that
ABS neither promoted nor inhibited the NBF of MTA.
In our opinion, this potent hemostatic agent may be
used in endodontic surgery owing to its biologic proper-
ties. However, further research is needed to clarify its
beneficial effects and to detect potential unfavorable
features.
Conclusions
Consequences of contamination of MTA with a new
plant-based hemostatic agent, ABS, was investigated in
an in vivo system to assess if it had an impact on MTA
function. ABS had no deleterious effects on the mode of
action of this root-end filling material.
Additional file
Additional file 1: The raw data. (DOCX 25 kb)
Abbreviations
ABS: Ankaferd Blood Stopper; FBR: Foreign body reaction; MTA: Mineral
trioxide aggregate; NBF: New bone formation
Acknowledgements
All authors declare that there is no funding in the current study.
Availibility of data and materials
The datasets supporting the conclusions of this article are included within
the article and its Additional file 1.
Authors’ contributions
MED performed animal experimentations and wrote the manuscript. HO and
BY contributed to planning and designing the study, in the data analysis and
submission of the mansucript. HE is supervisor of the study and assisted in
drafting of the manuscript. SG participated in all stages of the research and
helped to perform the animal experimentations. VO participated in the
methodology by suggesting the implantation of the tubes into the
medullary compartment and has microscopically examined the specimens
without any knowledge of the kind, composition and function of the
biomaterials. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Fig. 4 Tissue reactions in the MTA-ABS group. 7 days: a Fibrous band of connective tissue (bold arrow) and tiny bone trabeculae (arrow) adjacent
to the open end (H&E,x100). 30 days: b Lamellar bone (arrow) and bone marrow (bold arrow) at the open end of the tube (H&E,x200). 60 days: c
Mature lamellar bone (arrow) surrounding the open end of the tube (H&E,x200). 90 days: d Mature lamellar bone (arrow) and bone marrow
(bold arrow) (H&E,x100)
Dinçol et al. BMC Oral Health  (2016) 16:111 Page 8 of 9
Ethics approval and consent to participate
This in vivo, experimental study was conducted with the approval of the
Local Ethics Committee on Animal Research Laboratory of Istanbul University
(Vote number: 43/2009). Therefore, the informed concent was not applicable.
Author details
1Faculty of Dentistry, Department of Endodontics, Istanbul University, 34093,
Fatih, Istanbul, Turkey. 2Institute of Oncology, Department of Tumor
Pathology and Cytology, Istanbul University, 34093, Fatih, Istanbul, Turkey.
Received: 30 April 2016 Accepted: 23 September 2016
References
1. Martínez Lalis R, Esaín ML, Kokubu GA, Willis J, Chaves C, Grana DR. Rat
subcutaneous tissue response to modified Portland cement, a new mineral
trioxide aggregate. Braz Dent J. 2009;20:112–7.
2. Moretton TR, Brown Jr CE, Legan JJ, Kafrawy AH. Tissue reactions after
subcutaneous and intraosseous implantation of mineral trioxide aggregate
and ethoxybenzoic acid cement. J Biomed Mater Res. 2000;52:528–33.
3. Zhang W, Peng B. Tissue reactions after subcutaneous and intraosseous
implantation of iRoot SP, MTA and AH Plus. Dent Mater J. 2015;34:774–80.
4. Nekoofar MH, Oloomi K, Sheykhrezae MS, Tabor R, Stone DF, Dummer PM.
An evaluation of the effect of blood and human serum on the surface
microhardness and surface microstructure of mineral trioxide aggregate. Int
Endod J. 2010;43:849–58.
5. Scarano A, Artese L, Piattelli A, Carinci F, Mancino C, Iezzi G. Hemostasis
control in endodontic surgery: a comparative study of calcium sulfate
versus gauzes and versus ferric sulfate. J Endod. 2012;38:20–3.
6. Cintra LT, Ribeiro TA, Gomes-Filho JE, Bernabé PF, Watanabe S, Facundo AC,
et al. Biocompatibility and biomineralization assessment of a new root canal
sealer and root-end filling material. Dent Traumatol. 2013;29:145–50.
7. Rahimi S, Mokhtari H, Shahi S, Kazemi A, Asgary S, Eghbal MJ, Mesgariabbasi
M, et al. Osseous reaction to implantation of two endodontic cements:
Mineral trioxide aggregate (MTA) and calcium enriched mixture (CEM). Med
Oral Pathol Oral Cir Bucal. 2012;17:907–11.
8. Saidon J, He J, Zhu Q, Safavi K, Spångberg LS. Cell and tissue reactions to
mineral trioxide aggregate and Portland cement. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2003;95:483–9.
9. Rahimi S, Ghasemi N, Shahi S, Lotfi M, Froughreyhani M, Milani AS, et al.
Effect of blood contamination on the retention characteristics of two
endodontic biomaterials in simulated furcation perforations. J Endod. 2013;
39:697–700.
10. Oloomi K, Saberi E, Mokhtari H, Mokhtari Zonouzi HR, Nosrat A, Nekoofar
MH, et al. Evaluation of the effect of blood contamination on the
compressive strength of MTA modified with hydration accelerators. Restor
Dent Endod. 2013;38:128–33.
11. Sauveur G, Roth F, Sobel M, Boucher Y. The control of haemorrhage at the
operative site during periradicular surgery. Int Endod J. 1999;32:225–8.
12. Cinar C, Odabaş ME, Akca G, Işik B. Antibacterial effect of a new haemostatic
agent on oral microorganisms. J Clin Exp Dent. 2012;4:151–5.
13. Işler SC, Demircan S, Cakarer S, Cebi Z, Keskin C, Soluk M, et al. Effects of
folk medicinal plant extract Ankaferd Blood Stopper® on early bone healing.
J Appl Oral Sci. 2010;18:409–14.
14. Trakyali G, Oztoprak MO. Plant extract Ankaferd Blood Stopper effect on
bond strength. Angle Orthod. 2010;80:570–4.
15. Karakaya K, Ucan HB, Tascilar O, Emre AU, Cakmak GK, Irkorucu O, et al.
Evaluation of a new hemostatic agent Ankaferd Blood Stopper in
experimental liver laceration. J Invest Surg. 2009;22:201–6.
16. Okumus M, Yuksel KZ, Ozbag D, Cıralık H, Yılmaz Z, Gumusalan Y, et al.
Medicinal plant extract (Ankaferd Blood Stopper) application in deep tissue
injuries in rats: histopathological investigation of the effect on regional and
systemic tissues. Turkish Eur J Trauma Emerg Surg. 2013;19:1–7.
17. Çakarer S, Eyüpoğlu E, Günes ÇÖ, Köseoğlu BG, Berberoğlu HK, Keskin C.
Evaluation of the hemostatic effects of Ankaferd Blood Stopper during
dental extractions in patients on antithrombotic therapy. Clin Appl Thromb
Hemost. 2013;19:96–9.
18. Simşek HO, Tüzüm MŞ, Baykul T, Gürer IE, Başsorgun Cİ. Experimental
investigation of the effects of a blood stopper agent (Ankaferd Blood
Stopper) on bone surfaces. Turk J Haematol. 2013;30:177–83.
19. Kurt M, Oztas E, Kuran S, Onal IK, Kekilli M, Haznedaroglu IC. Tandem oral,
rectal, and nasal administrations of Ankaferd Blood Stopper to control
profuse bleeding leading to hemodynamic instability. Am J Emerg Med.
2009;27:631.
20. Jang Y, Kim H, Roh BD, Kim E. Biologic response of local hemostatic agents
used in endodontic microsurgery. Restor Dent Endod. 2014;39:79–88.
21. Jensen SS, Yazdi PM, Hjørting-Hansen E, Bosshardt DD, von Arx T.
Haemostatic effect and tissue reactions of methods and agents used for
haemorrhage control in apical surgery. Int Endod J. 2010;43:57–63.
22. Olsen FK, Austin BP, Walia H. Osseous reaction to implanted ZOE retrograde
filling materials in the tibia of rats. J Endod. 1994;20:389–94.
23. Torabinejad M, Ford TR, Abedi HR, Kariyawasam SP, Tang HM. Tissue
reaction to implanted root-end filling materials in the tibia and mandible of
guinea pigs. J Endod. 1998;24:468–71.
24. Tassery H, Pertot WJ, Camps J, Proust JP, Déjou J. Comparison of two
implantation sites for testing intraosseous biocompatibility. J Endod. 1999;
25:615–8.
25. Yavari HR, Shahi S, Rahimi S, Shakouie S, Roshangar L, Abassi MM, et al.
Connective tissue reaction to white and gray MTA mixed with distilled
water or chlorhexidine in rats. Iran Endod J. 2009;4:25–30.
26. Saghiri MA, Tanideh N, Garcia-Godoy F, Lotfi M, Karamifar K, Amanat D.
Subcutaneous connective tissue reactions to various endodontic biomaterials:
an animal study. J Dent Res Dent Clin Dent Prospect. 2013;7:15–21.
27. Tasdelen Fisgin N, Tanriverdi Cayci Y, Coban AY, Ozatli D, Tanyel E,
Durupinar B, et al. Antimicrobial activity of plant extract Ankaferd Blood
Stopper. Fitoterapia. 2009;80:48–50.
28. Cunha SA, Rached Jr FJ, Alfredo E, León JE, Perez DE. Biocompatibility of
sealers used in apical surgery: a histological study in rat subcutaneous
tissue. Braz Dent J. 2011;22:299–305.
29. Cotran RS, Kumar V, Robbins SL. Robbins pathologic basis of disease.
Volume chapter 2. UK: Harcourt Brace Jovanovich Inc; 1989.
30. Scarparo RK, Haddad D, Acasigua GA, Fossati AC, Fachin EV, Grecca FS.
Mineral trioxide aggregate-based sealer: analysis of tissue reactions to a
new endodontic material. J Endod. 2010;36:1174–8.
31. Lotfi M, Vosoughhosseini S, Saghiri MA, Mesgariabbasi M, Ranjkesh B. Effect
of white mineral trioxide aggregate mixed with disodium hydrogen
phosphate on inflammatory cells. J Endod. 2009;35:703–5.
32. Eghbal MJ, Asgary S, Baglue RA, Parirokh M, Ghoddusi J. MTA pulpotomy of
human permanent molars with irreversible pulpitis. Aust Endod J. 2009;35:4–8.
33. Samiee M, Eghbal MJ, Parirokh M, Abbas FM, Asgary S. Repair of furcal
perforation using a new endodontic cement. Clin Oral Investig. 2010;14:653–8.
34. Gomes-Filho JE, Watanabe S, Bernabe PF, de Moares Costa MT. A mineral
trioxide aggregate sealer stimulated mineralization. J Endod. 2009;35:256–60.
35. Emes Y, Aybar B, Vural P, İşsever H, Yalçin S, Atalay B, et al. Effects of
hemostatic agents on fibroblast cells. Implant Dent. 2014;23:641–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dinçol et al. BMC Oral Health  (2016) 16:111 Page 9 of 9
